Publications by authors named "Rayne H Rouce"

Claim this Profile
C
Clearing the hurdles for CAR-T cell treatment.
Rayne H Rouce

Nat Rev Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conquering the gene and cell therapy viability crisis: A path paved by ASGCT.
Rayne H Rouce

Mol Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
Samuel John, Kevin J Curran, Erin M Hall, Amy K Keating, Susanne H C Baumeister, Rayne H Rouce

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel.
Swati Naik, Subodh Selukar, Aimee C Talleur, Samira Deshpande, Gabriela Llaurador Caraballo, Rayne H Rouce

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities and Challenges With CAR T-cell Treatment of Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia: Review and Recommendations From the Westhafen Intercontinental Group.
Candelaria Deimundo Roura, Persis Amrolia, Marc Ansari, Peter Bader, Adriana Balduzzi, Rayne H Rouce

Transplant Cell Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing STEMM Education Through Advanced Technologies and Collaborative Programs.
Zhongcheng Shi, Michael Nguyen, Yuan Yao, Debra D Murray, Rayne H Rouce

J Biomol Tech· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How I Approach Ethical Considerations for Pediatric Phase I CAR T-Cell Trials.
Sarah W Peters, Sara K Silbert, Elizabeth M Holland, Annette Rid, Rayne H Rouce

Pediatr Blood Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rest, then rejuvenate: CD19 boost to improve CAR persistence.
Rayne H Rouce

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How to democratize cell and gene therapy: A global approach.
Rayne H Rouce, Bambi J Grilley

Mol Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.
Aaron B Ross, Kriti Puri, Thomas L Johnson, Lilliam D Correa, Tami D John, Rayne H Rouce

Pediatr Blood Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas.
Yomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, Helen E Heslop, Rayne H Rouce

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis.
Andrew D J Pearson, Claudia Rossig, Crystal L Mackall, Nirali N Shah, André Baruchel, Rayne H Rouce

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
American Society of Hematology: building a comprehensive minority recruitment and retention professional program.
Margo R Rollins, Rahma M Warsame, Melody Smith, Arturo Molina, Rayne H Rouce

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV and post-transplant lymphoproliferative disorder: a complex relationship.
Nader Kim El-Mallawany, Rayne H Rouce

Hematology Am Soc Hematol Educ Program· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
Anne Miller, Rachel Daum, Tao Wang, Mengfen Wu, Candise Tat, Rayne H Rouce

Cytotherapy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.
Rebecca A Gardner, Claire White, Magdi Elsallab, Stephanie Farnia, Ellen Fraint, Rayne H Rouce

Transplant Cell Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell and gene therapy accessibility.
Rayne H Rouce, Matthew H Porteus

Science· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential EBV protein-specific antibody response between responders and non-responders to EBVSTs immunotherapy.
Yomani D Sarathkumara, Nathan W Van Bibber, Zhiwei Liu, Helen E Heslop, Rayne H Rouce

bioRxiv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults.
Adam J Lamble, Liora M Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity.
Royce Ma, Mae Woods, Phillip Burkhardt, Noah Crooks, Dayenne G van Leeuwen, Rayne H Rouce

Cell Rep Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas.
LaQuisa C Hill, Rayne H Rouce, Mengfen J Wu, Tao Wang, Royce Ma

Blood· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mediport use as an acceptable standard for CAR T cell infusion.
Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J M King, Dhruv Bhatt, Rayne H Rouce

Front Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted cellular therapy for treatment of relapsed or refractory leukemia.
Lauren D Scherer, Rayne H Rouce

Best Pract Res Clin Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Jay A Read, Rayne H Rouce, Feiyan Mo, Maksim Mamonkin, Katherine Y King

Transplant Cell Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access offsets poverty in quest for CAR T cells.
Rayne H Rouce, Eneida Nemecek

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis